BCR/ABL induces chromosomal instability after genotoxic stress and alters the cell death threshold

被引:26
作者
Dierov, J. [1 ]
Sanchez, P. V. [1 ]
Burke, B. A. [1 ]
Padilla-Nash, H. [2 ]
Putt, M. E. [3 ]
Ried, T. [2 ]
Carroll, M. [1 ]
机构
[1] Univ Penn, Div Hematol & Oncol, Dept Med, Philadelphia, PA 19104 USA
[2] NCI, Sect Canc Gen, Genet Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
基金
美国国家卫生研究院;
关键词
BCR/ABL; chronic myeloid leukemia; etoposide; spectral karyotyping (SKY); genomic instability; CHRONIC MYELOID-LEUKEMIA; BCR-ABL; CLONAL EVOLUTION; TYROSINE KINASE; DNA-DAMAGE; APOPTOSIS; ABERRATIONS; INHIBITION; EXPRESSION; IMATINIB;
D O I
10.1038/leu.2008.308
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Earlier reports have suggested that the BCR/ABL oncogene, associated with chronic myeloid leukemia, induces a mutator phenotype; however, it is unclear whether this leads to long-term changes in chromosomes and whether the phenotype is found in primary chronic myelogeneous leukemia (CML) cells. We have addressed both these issues. BCR/ABL-expressing cell lines show an increase in DNA breaks after treatment with etoposide as compared to control cells. However, although BCR/ABL-expressing cell lines have an equivalent cell survival, they have an increase in chromosomal translocations after DNA repair as compared to control cells. This demonstrates that BCR/ABL expression decreases the fidelity of DNA repair. To see whether this is true in primary CML samples, normal CD34+ progenitor cells and CML progenitor cells were treated with etoposide. CML progenitor cells have equivalent survival but have an increase in DNA double-strand breaks (DSBs). Spectral karyotyping demonstrates new chromosomal translocations in CML cells, but not normal progenitor cells, consistent with error-prone DNA repair. Taken together, these data demonstrate that BCR/ABL enhances the accumulation of DSBs and alters the apoptotic threshold in CML leading to error-prone DNA repair.
引用
收藏
页码:279 / 286
页数:8
相关论文
共 29 条
[1]   APOPTOSIS IN CHRONIC MYELOID-LEUKEMIA - NORMAL RESPONSES BY PROGENITOR CELLS TO GROWTH-FACTOR DEPRIVATION, X-IRRADIATION AND GLUCOCORTICOIDS [J].
AMOS, TAS ;
LEWIS, JL ;
GRAND, FH ;
GOODING, RP ;
GOLDMAN, JM ;
GORDON, MY .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 91 (02) :387-393
[2]  
BEDI A, 1994, BLOOD, V83, P2038
[3]   BCR-ABL-MEDIATED INHIBITION OF APOPTOSIS WITH DELAY OF G2/M TRANSITION AFTER DNA-DAMAGE - A MECHANISM OF RESISTANCE TO MULTIPLE ANTICANCER AGENTS [J].
BEDI, A ;
BARBER, JP ;
BEDI, GC ;
ELDEIRY, WS ;
SIDRANSKY, D ;
VALA, MS ;
AKHTAR, AJ ;
HILTON, J ;
JONES, RJ .
BLOOD, 1995, 86 (03) :1148-1158
[4]   The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells [J].
Deininger, Michael W. N. ;
Cortes, Jorge ;
Paquette, Ron ;
Park, Byung ;
Hochhaus, Andreas ;
Baccarani, Michele ;
Stone, Richard ;
Fischer, Thomas ;
Kantarjian, Hagop ;
Niederwieser, Dietger ;
Gambacorti-Passerini, Carlo ;
So, Charlene ;
Gathmann, Insa ;
Goldman, John M. ;
Smith, Douglas ;
Druker, Brian J. ;
Guilhot, Francois .
CANCER, 2007, 110 (07) :1509-1519
[5]   BCR-ABL down-regulates the DNA repair protein DNA-PKcs [J].
Deutsch, E ;
Dugray, A ;
AbdulKarim, B ;
Marangoni, E ;
Maggiorella, L ;
Vaganay, S ;
M'Kacher, R ;
Rasy, SD ;
Eschwege, F ;
Vainchenker, W ;
Turhan, AG ;
Bourhis, J .
BLOOD, 2001, 97 (07) :2084-2090
[6]   Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells [J].
Deutsch, E ;
Jarrousse, S ;
Buet, D ;
Dugray, A ;
Bonnet, ML ;
Vozenin-Brotons, MC ;
Guilhot, F ;
Turhan, AG ;
Feunteun, J ;
Bourhis, J .
BLOOD, 2003, 101 (11) :4583-4588
[7]   BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint [J].
Dierov, J ;
Dierova, R ;
Carroll, M .
CANCER CELL, 2004, 5 (03) :275-285
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]   Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J].
Druker, Brian J. ;
Guilhot, Francois ;
O'Brien, Stephen G. ;
Gathmann, Insa ;
Kantarjian, Hagop ;
Gattermann, Norbert ;
Deininger, Michael W. N. ;
Silver, Richard T. ;
Goldman, John M. ;
Stone, Richard M. ;
Cervantes, Francisco ;
Hochhaus, Andreas ;
Powell, Bayard L. ;
Gabrilove, Janice L. ;
Rousselot, Philippe ;
Reiffers, Josy ;
Cornelissen, Jan J. ;
Hughes, Timothy ;
Agis, Hermine ;
Fischer, Thomas ;
Verhoef, Gregor ;
Shepherd, John ;
Saglio, Giuseppe ;
Gratwohl, Alois ;
Nielsen, Johan L. ;
Radich, Jerald P. ;
Simonsson, Bengt ;
Taylor, Kerry ;
Baccarani, Michele ;
So, Charlene ;
Letvak, Laurie ;
Larson, Richard A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (23) :2408-2417
[10]   CHRONIC MYELOCYTIC-LEUKEMIA - CLONAL ORIGIN IN A STEM-CELL COMMON TO GRANULOCYTE, ERYTHROCYTE, PLATELET AND MONOCYTE-MACROPHAGE [J].
FIALKOW, PJ ;
JACOBSON, RJ ;
PAPAYANNOPOULOU, T .
AMERICAN JOURNAL OF MEDICINE, 1977, 63 (01) :125-130